{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:52:21Z","timestamp":1770072741720,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess responsiveness of the spondyloarthritis (SpA)-specific universal health utility from the ASAS Health Index (U-ASAS-HI) compared with generic health utilities (EQ-5D-5L and SF-6D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were used from patients with SpA participating in the ASAS-HI international validation study and starting TNF inhibitor (TNFi), conventional synthetic DMARD (csDMARD) or NSAID. A priori hypotheses on correlation of change in utility and change in external health anchors between baseline and follow-up were tested. Standardized response mean (SRM) and Cohen\u2019s effect size (ES) were calculated in each treatment group. The ability of changes in utilities to discriminate between BASDAI-50% (non)-responders was assessed by standardized estimate of change and receiver operating characteristic (ROC) analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>219 patients were included (110 TNFi, 37 csDMARD, and 72 NSAID). Mean (s.d.) age was 37 (13) years and 63% were male. Hypotheses on correlations of change scores were confirmed for 75% of comparisons for U-ASAS-HI and EQ-5D-5L, but not for SF-6D. As expected, SRM and ES for the U-ASAS-HI were large in the TNFi-treated group, moderate in the csDMARD group and small to moderate in the NSAID group. The hypothesized larger SRM and ES for U-ASAS-HI compared with EQ-5D and SF-6D could not be consistently confirmed across the three treatment groups. Ability to discriminate between BASDAI-50% responders and non-responders did not differ among utility instruments in ROC comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a context where change is expected, the SpA-specific U-ASAS-HI correlates as expected with changes in other SpA-specific outcomes and shows good responsiveness, which is similar to but not better than for generic utilities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf554","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:29:55Z","timestamp":1760959795000},"source":"Crossref","is-referenced-by-count":0,"title":["Responsiveness of spondyloarthritis-specific health utilities based on the ASAS Health Index (U-ASAS-HI): an ancillary analysis from the ASAS-HI validation study"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-025X","authenticated-orcid":false,"given":"Omar-Javier","family":"Calixto","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Rheumazentrum Ruhrgebiet , Herne,","place":["Germany"]},{"name":"Medical School, Ruhr-Universit\u00e4t Bochum , Bochum,","place":["Germany"]},{"name":"Clinical Immunology Group, Universidad Militar Nueva Granada , Bogot\u00e1,","place":["Colombia"]},{"name":"Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque , Bogot\u00e1,","place":["Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rheumazentrum Ruhrgebiet , Herne,","place":["Germany"]},{"name":"Medical School, Ruhr-Universit\u00e4t Bochum , Bochum,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-9533","authenticated-orcid":false,"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Maastricht University Medical Centre , Maastricht,","place":["The Netherlands"]},{"name":"Care & Public Health Research Institute (Caphri), Maastricht University , Maastricht,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-9542","authenticated-orcid":false,"given":"Wilson","family":"Bautista-Molano","sequence":"additional","affiliation":[{"name":"Clinical Immunology Group, Universidad Militar Nueva Granada , Bogot\u00e1,","place":["Colombia"]},{"name":"Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque , Bogot\u00e1,","place":["Colombia"]},{"name":"Department of Rheumatology, Hospital Universitario Fundaci\u00f3n Santa Fe de Bogot\u00e1 , Bogot\u00e1,","place":["Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-4429","authenticated-orcid":false,"given":"Ivette","family":"Essers","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Maastricht University Medical Centre , Maastricht,","place":["The Netherlands"]},{"name":"Care & Public Health Research Institute (Caphri), Maastricht University , Maastricht,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"Juergen","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rheumatologisches Versorgungszentrum Steglitz , Berlin,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rheumazentrum Ruhrgebiet , Herne,","place":["Germany"]},{"name":"Medical School, Ruhr-Universit\u00e4t Bochum , Bochum,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026020205383279100_keaf554-B1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0272989X13500720","article-title":"A Comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes","volume":"34","author":"Hern\u00e1ndez Alava","year":"2014","journal-title":"Med Decis Making"},{"key":"2026020205383279100_keaf554-B2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jval.2015.02.016","article-title":"Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods","volume":"18","author":"Wailoo","year":"2015","journal-title":"Value Health"},{"key":"2026020205383279100_keaf554-B3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11136-008-9420-8","article-title":"Comparing SF-6D and EQ-5D utilities across groups differing in health status","volume":"18","author":"Kontodimopoulos","year":"2009","journal-title":"Qual Life Res"},{"key":"2026020205383279100_keaf554-B4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/14737167.8.5.453","article-title":"Converting condition-specific measures into preference-based outcomes for use in economic evaluation","volume":"8","author":"Petrillo","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026020205383279100_keaf554-B5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14656566.8.5.633","article-title":"Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease","volume":"8","author":"Simoens","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"2026020205383279100_keaf554-B6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.36469\/001c.83387","article-title":"QALYs: the math doesn\u2019t work","volume":"10","author":"Sawhney","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"key":"2026020205383279100_keaf554-B7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","article-title":"Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS","volume":"74","author":"Kiltz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026020205383279100_keaf554-B8","first-page":"S105","article-title":"The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis","volume":"32","author":"Kiltz","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205383279100_keaf554-B9","doi-asserted-by":"crossref","first-page":"e000872","DOI":"10.1136\/rmdopen-2018-000872","article-title":"Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI","volume":"5","author":"Essers","year":"2019","journal-title":"RMD Open"},{"key":"2026020205383279100_keaf554-B10","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1093\/rheumatology\/keaf056","article-title":"Performance of spondyloarthritis-specific health utilities based on the ASAS Health Index: an ancillary analysis from the ASAS-HI validation study","volume":"64","author":"Calixto","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205383279100_keaf554-B11","first-page":"5","author":"Beaton","year":"2021"},{"key":"2026020205383279100_keaf554-B12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","article-title":"Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis","volume":"77","author":"Kiltz","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026020205383279100_keaf554-B13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy (New York)"},{"key":"2026020205383279100_keaf554-B14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"key":"2026020205383279100_keaf554-B15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"2026020205383279100_keaf554-B16","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2026020205383279100_keaf554-B17","first-page":"30","volume-title":"SF36 health survey: manual and interpretation guide","author":"Ware","year":"1993"},{"key":"2026020205383279100_keaf554-B18","first-page":"69","article-title":"Statistics corner: a guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med J"},{"key":"2026020205383279100_keaf554-B19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"2026020205383279100_keaf554-B20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor \u03b1 blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2026020205383279100_keaf554-B21","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/rheumatology\/kew238","article-title":"Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index","volume":"55","author":"Kiltz","year":"2016","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf554\/64855823\/keaf554.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf554\/64855823\/keaf554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf554\/64855823\/keaf554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:38:38Z","timestamp":1770028718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf554\/8296873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf554","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,22]]},"article-number":"keaf554"}}